| REG |
Report |
Core Operating Earnings per share |
BEAT |
pred ~$1.16 vs. cons $1.14 |
MEDIUM |
| REG |
Report |
Nareit FFO per diluted share |
IN-LINE |
pred ~$1.19 vs. cons $1.18 |
MEDIUM |
| REG |
Report |
Same-property NOI growth |
IN-LINE |
pred ~2.6% vs. cons 2.5% |
MEDIUM |
| REG |
Guide |
FY2026 Core Operating Earnings per share |
UNCHANGED |
guide ~$4.61 vs. cons $4.61 (FY2026) |
HIGH |
| REG |
Guide |
FY2026 same-property NOI growth |
UNCHANGED |
guide ~3.50% vs. cons 3.50% (FY2026) |
HIGH |
| REG |
Guide |
FY2026 development and redevelopment spend |
BETTER |
guide ~$375M vs. cons $350M (FY2026) |
MEDIUM |
| REG |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.2% |
— |
MEDIUM |
| REG |
Return |
5-day cumulative residual |
+0.4% (FADE) |
A modest ~$0.02 Core Operating Earnings beat and healthy ~2.6% same-property NOI should support an initial positive reaction, but maintaining FY2026 Core Operating Earnings near ~$4.61 versus ~$4.61 consensus leaves limited out-period estimate upside; higher ~$375M development spend versus ~$350M consensus is strategically positive but is more weighted to 2027+ earnings. |
MEDIUM |